Brief: Aclaris Therapeutics Initiates Phase 1A/1B Program For Its Novel Bispecific Antibody Ati-052
23/06/2025 12:04
June 23 (Reuters) - Aclaris Therapeutics Inc ACRS.O: ACLARIS THERAPEUTICS INITIATES PHASE 1A/1B PROGRAM FOR ITS NOVEL BISPECIFIC ANTIBODY ATI-052 ACLARIS THERAPEUTICS INC - PHASE 1A RESULTS EXPECTED EARLY 2026, PHASE 1B RESULTS IN H2 2026 Source text: ID:nGNX4hSPsB Further company coverage: ACRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations